相似文献
1
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
Vaccine. 2010 Apr 9;28(17):3025-9. doi: 10.1016/j.vaccine.2009.10.152. Epub 2009 Nov 18.
2
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.
J Infect Dis. 2012 Oct 1;206(7):1069-77. doi: 10.1093/infdis/jis402. Epub 2012 Aug 13.
3
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Vaccine. 2008 Aug 5;26(33):4160-7. doi: 10.1016/j.vaccine.2008.05.077. Epub 2008 Jun 13.
4
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
PLoS One. 2019 Sep 18;14(9):e0222178. doi: 10.1371/journal.pone.0222178. eCollection 2019.
5
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
N Engl J Med. 2006 Mar 30;354(13):1343-51. doi: 10.1056/NEJMoa055778.
6
Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
Vaccine. 2009 Jul 30;27(35):4834-9. doi: 10.1016/j.vaccine.2009.05.066. Epub 2009 Jun 11.
7
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
J Microbiol Immunol Infect. 2019 Oct;52(5):685-692. doi: 10.1016/j.jmii.2019.03.009. Epub 2019 May 18.
8
The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
J Microbiol Immunol Infect. 2013 Dec;46(6):448-55. doi: 10.1016/j.jmii.2012.08.002. Epub 2012 Sep 27.
9
Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Vaccine. 2009 Dec 30;27 Suppl 6:G60-6. doi: 10.1016/j.vaccine.2009.10.031.
10
Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
Clin Infect Dis. 2016 Feb 1;62(3):383-391. doi: 10.1093/cid/civ884. Epub 2015 Oct 20.
引用本文的文献
1
Summary of the National Advisory Committee on Immunization (NACI) Statement-Recommendations on Fractional Influenza Vaccine Dosing in the Event of a Shortage: Pandemic preparedness.
Can Commun Dis Rep. 2023 Apr 1;49(4):90-98. doi: 10.14745/ccdr.v49i04a01.
2
Study of Antibody-Dependent Reactions of Mast Cells and in a Model of Severe Influenza Infection in Mice.
Front Immunol. 2021 Jul 14;12:689436. doi: 10.3389/fimmu.2021.689436. eCollection 2021.
3
Assessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs.
Vaccines (Basel). 2021 Mar 13;9(3):258. doi: 10.3390/vaccines9030258.
4
Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2021 Feb 1;4(2):e2035693. doi: 10.1001/jamanetworkopen.2020.35693.
5
Mast cell degranulation and histamine release during A/H5N1 influenza infection in influenza-sensitized mice.
Life Sci. 2020 Oct 1;258:118230. doi: 10.1016/j.lfs.2020.118230. Epub 2020 Aug 8.
6
H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines.
NPJ Vaccines. 2017 Jun 8;2:16. doi: 10.1038/s41541-017-0017-5. eCollection 2017.
7
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
J Infect Dis. 2016 Oct 1;214(7):1020-9. doi: 10.1093/infdis/jiw310. Epub 2016 Jul 20.
8
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.
Vaccine. 2016 Jan 20;34(4):547-554. doi: 10.1016/j.vaccine.2015.11.055. Epub 2015 Dec 4.
9
Refining the approach to vaccines against influenza A viruses with pandemic potential.
Future Virol. 2015;10(9):1033-1047. doi: 10.2217/fvl.15.69.
10
Effect of vaccine administration modality on immunogenicity and efficacy.
Expert Rev Vaccines. 2015;14(11):1509-23. doi: 10.1586/14760584.2015.1081067. Epub 2015 Aug 27.
本文引用的文献
1
Influenza vaccination; comparison of intracutaneous and subcutaneous methods.
U S Nav Med Bull. 1947 Jan-Feb;47(1):197-206.
2
THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.
J Exp Med. 1937 Jan 31;65(2):251-9. doi: 10.1084/jem.65.2.251.
3
Immunologic reactions following the intradermal inoculation of influenza A and B vaccine.
Proc Soc Exp Biol Med. 1948 Jan;67(1):96-101. doi: 10.3181/00379727-67-16216.
4
Influenza vaccination; a comparison of antibody response obtained by various methods of administration.
J Immunol. 1949 May;62(1):1-11.
5
Influenza vaccine; a study of serologic responses and incidence of reactions following subcutaneous and intradermal inoculation.
Am J Dis Child (1911). 1949 Feb;77(2):149-63.
6
Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients.
Am J Transplant. 2007 Nov;7(11):2567-72. doi: 10.1111/j.1600-6143.2007.01982.x. Epub 2007 Oct 1.
7
Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
Pediatrics. 2007 Jun;119(6):1076-82. doi: 10.1542/peds.2006-3176.
8
Antibody responses after dose-sparing intradermal influenza vaccination.
Vaccine. 2007 Jan 8;25(4):659-63. doi: 10.1016/j.vaccine.2006.08.026. Epub 2006 Sep 1.
9
Reduced-dose influenza vaccine.
Ann Pharmacother. 2006 Sep;40(9):1635-9. doi: 10.1345/aph.1G645. Epub 2006 Jul 11.
10
The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients.
Arch Intern Med. 2006 Jul 10;166(13):1417. doi: 10.1001/archinte.166.13.1417.
Zotero 插件